Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price target on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Stock Down 0.6 %

NASDAQ:ARTV opened at $10.58 on Monday. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31. The stock’s 50-day simple moving average is $11.41.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, equities analysts predict that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at approximately $42,000. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the third quarter worth about $135,000. JPMorgan Chase & Co. bought a new position in shares of Artiva Biotherapeutics in the third quarter valued at approximately $166,000. Barclays PLC purchased a new position in Artiva Biotherapeutics during the third quarter valued at approximately $304,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Artiva Biotherapeutics in the 3rd quarter valued at $623,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.